| INTRODUC TI ON
Nonalcoholic fatty liver disease (NAFLD) is characterised by fat accumulation (or steatosis) in >5% of hepatocytes in individuals who either consume little alcohol or have no other secondary causes of steatosis such as viral hepatitis, lipodystrophy or medications associated with the development of steatosis. 1, 2 The increasing prevalence of NAFLD parallels rises in the incidence of obesity and insulin resistance. 3, 4 NAFLD is among the most common causes of liver disease and liver transplantation in the Western hemisphere. 4 ,5 NAFLD can be sub-classified into two categories: the non-progressive form, nonalcoholic fatty liver (NAFL) and the progressive form, nonalcoholic steatohepatitis (NASH). 1, 6 NASH is a clinic-pathologic entity that is typically characterised by the presence of zone 3 steatosis, ballooning and lobular inflammation; perisinusoidal fibrosis may or may not be also present. 1, 7 Fibrosis progression rate is estimated to be higher in NASH than in NAFL and progression to cirrhosis may take up to 30 years; however, rapid progression to cirrhosis may occur in a small subset of patients. 8 In addition, NASH is associated with increased risk of hepatocellular carcinoma (HCC) and all-cause (cardiovascular and liver-related) mortality. [9] [10] [11] NAFLD pathogenesis is related to multiple insults that occur simultaneously and may act synergistically, 12, 13 including accumulation of triglycerides (TGs), 12 mitochondrial dysfunction and increased oxidative stress, [12] [13] [14] altered mechanisms of apoptosis and autophagy, 15, 16 increased levels of toxic lipid-related factors (eg, free fatty acids) 12 and liver inflammation. 12 Genetics (eg, mutations in the patatin-like phospholipase domain-containing 3 gene) 17 and adverse consequences of dietary habits and sedentary lifestyle (eg, insulin resistance, central obesity, dyslipidaemia and hypertriglyceridemia) likely contribute to overall NAFLD pathophysiology and augment the underlying mechanisms of liver insult.
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Accumulating evidence also implicates the gut microbiota in the development and progression of NAFLD 18, 19 and suggests that therapeutic agents that target the gut microbiota may be beneficial.
This review examines the pathophysiologic implications of altered gut microbiota in NAFLD and highlights recent progress in the development of microbiota-targeting therapies for patients with liver disease.
| MATERIAL S AND ME THODS
A PubMed search was performed for English language articles published between January 1, 2002 and January 31, 2019. Search terms included "cirrhosis" or "insulin resistance" or "liver disease" or "metabolic syndrome" or "NAFLD" or "obesity" or "steatohepatitis" and "microbiome." The search was initially limited to primary publications and those of human subjects; articles reporting animal studies were later retrieved to allow more thorough discussion of patho-
physiology. An additional nonsystematic search was performed to gather data on the use of prebiotics, probiotics, symbiotics, synbiotics and antibiotics for NAFLD. A total of 230 articles were retrieved; of these, 60 articles were reviewed. In addition, the bibliographies of these 60 articles were reviewed for additional relevant articles to consider for inclusion.
| MI CROB I OTA , MI CROB I OME AND THE G UT
The term "microbiota" refers to a community of microbes in an organism, whereas "microbiome" is used to refer to both the microbiota and the collective genomes and gene products of the microbiota living in or on an organism. The gastrointestinal (GI) tract of humans contains 10 trillion to 100 trillion bacteria, with approximately 15 000-36 000 species. 20, 21 Composition of the gut microbiota varies among individuals as the result of multiple intrinsic (eg, age 22, 23 ) and extrinsic (eg, method of feeding after birth 24, 25 and geographic region inhabited 26 ) aspects.
| ROLE OF G UT MI CROB I OME IN MAINTAINING HOMEOS TA S IS
Progressing along the human GI tract from the jejunum to the colon, the number and the diversity of bacteria increases, 27 and the predominant bacterial species change. In the upper GI tract (oesophagus and proximal small bowel), Streptococcus species predominate, 28 The interconnection between the gut microbiome and the host is complex. The host provides both a suitable environment and nutrients for bacterial growth, and the host's diet, disease states and medications affect gut bacteria. 33 The gut microbiota can, in turn, affect host nutrient and drug metabolism, contribute to maintaining the mucosal barrier of the GI tract, affect mucosal immunity and contribute to disease states. 34 
| G UT MI CROB I OME AND ME TABOLI C SYNDROME
Metabolic syndrome is defined as the presence of any three of the following conditions: central obesity, hypertension, impaired glucose tolerance (or overt diabetes mellitus), hypertriglyceridemia and low levels of high-density lipoproteinemia (HDL). 58 Given the close association between NAFLD and obesity, insulin resistance and TG levels, 59 NAFLD is often considered the hepatic manifestation of metabolic syndrome. 60 Because gut microbiota play a key role in metabolism and energy production from dietary intake, 61 it stands to reason that they are closely related to components of metabolic syndrome (eg, obesity and diabetes).
One of the main factors in the development of obesity, diabetes and NAFLD is diet. Diet affects the composition of GI bacteria, which then influences host metabolism and inflammation. 62 Turnbaugh and colleagues demonstrated the effect of diet on the gut microbiota in a mouse model. 63 They humanised the gut microbiota of these mice by transplanting them with human faeces, and then they fed the mice either a high-fat, high-sugar diet ("Western diet") or a plant-based, low-fat diet. 63 The group that was fed a high-fat diet had a lower percentage of Bacteroidetes spp in its gut microbiota and a higher percentage of Firmicutes compared with mice fed a plant-based diet.
Studies in humans and mice have shown an increased Firmicutes/ Bacteroidetes ratio in individuals who are overweight or obese, 64, 65 and a reduction in the Firmicutes/Bacteroidetes ratio with weight loss. 32 In addition, higher colonic levels of SCFAs have been observed in obese individuals compared with their nonobese counterparts. 64, 66, 67 The higher production of SCFAs may result in energy accumulation and subsequent weight gain. 68 In a comparison between individuals who were morbidly obese and individuals of normal weight, increased numbers of both the H 2 -producing bacteria Prevotellaceae and H 2 -oxidising Archaea microorganisms were observed in the morbidly obese participants. 69 The authors hypothesised that inter- 73 The gut microbiota may also inhibit activity of the enzyme, adenosine monophosphate-activated protein kinase, in muscle and liver, resulting in reduction of fatty acid oxidation and increased fat storage. 74, 75 The gut microbiome also has a role in type 2 diabetes mellitus (T2DM). For example, a correlation between the Firmicutes/ Bacteroidetes ratio and plasma glucose concentrations was reported in patients with T2DM. 76 In addition, as stated above, the gut microbiota affect the production and release of GLP-1, which affects pancreatic β-cell function. SCFAs also appear to be closely interrelated with insulin resistance. Compared with patients without insulin resistance, patients with T2DM have a decrease in butyrate-producing bacteria. 77 SCFAs bind to G-protein (GPR)-coupled receptors (eg, GPR41 and GPR43), 78 which may lead to the secretion of factors such as protein YY that affect satiety, gastric motility and pancreatic function.
79-81
SCFAs also regulate various aspects of GI inflammation, such as neutrophil migration, T-cell differentiation and macrophage expression of proinflammatory cytokines. 82 Insulin resistance is often accompanied by low-grade inflammation. 83, 84 The movement of the GI bacterial product lipopolysaccharides [LPS] into intestinal capillaries may contribute to inflammation and insulin resistance. 84 TLRs are a type of innate immune receptor that are thought to recognise LPS and other products of invading pathogenic bacteria. 83 TLR knockout studies in mice are helping to elucidate the role of the gut microbiota in metabolic syndrome and insulin resistance. For example, mice deficient in TLR-5 developed features of metabolic syndrome, including insulin resistance. 85 The authors of this report suggested that changes in the composition of gut microbiota, resulting from loss of TLR-5, induced the low-grade inflammation that contributed to the symptoms of metabolic syndrome. Another report described mice with elimination of TLR-4 specifically in hepatocytes. 86 When these mice received a high-fat diet, they became obese, but compared with control mice, these mice displayed enhanced insulin sensitivity and reduced hepatic steatosis. Thus, hepatocytes are centrally involved in the effects of inflammation on metabolic control, with the gut microbiota making up a significant part of that inflammatory signal. 86 
| G UT MI CROB I OME AND NAFLD
The major NAFLD risk factors (ie, diet, obesity and insulin resistance)
are closely connected with the gut microbiome ( Figure 1 ). 14, 62, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] It is reasonable to speculate that the gut microbiota and the pathophysiology of NASH are closely intertwined. One study found that the gut microbiota play a large role in the development of NAFLD, by transplanting the gut microbiota from mice with diet-induced NAFLD into germ-free mice; NAFLD developed in the initially germ-free mice. 18 In humans, characterisation of the faecal microbiomes of 86 patients with biopsy-proven NAFLD (n = 72, stages 0-2 fibrosis; n = 14, stages 3-4 [advanced] fibrosis) revealed that patients with NAFLD and advanced fibrosis had increased levels of Proteobacteria, whereas patients with mild fibrosis had increased levels of Firmicutes. 19 In addition, 37 of 40 features that were predictors of advanced fibrosis in patients with NAFLD were related to the gut microbiota.
Patients with NAFLD have increased intestinal permeability related to disrupted tight junctions. 97 As mentioned previously, increased GI "leakiness" may allow bacterial translocation and entry of bacteria-derived products into the portal circulation. 98, 99 Once in the liver, these factors may initiate proinflammatory cascades (eg, production of interleukin-6 [IL-6] and TNF-α) via interaction with the TLR present on a variety of cell types (ie, Kupffer cells, stellate cells and hepatocytes). 100 In fact, more than half of patients with NAFLD may have small-intestinal bacterial overgrowth, 97 and the presence of this comorbid condition parallels cirrhosis severity (ie,
Child-Turcotte-Pugh class). 101, 102 Inflammation is a key factor in the development of NASH, and LPS produced by GI bacteria trigger proinflammatory cytokine cascades that involve TLR-4 and nuclear factor kappa B (NFκB).
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LPS are also, as mentioned earlier, a key factor in the activation of and decreased abundance of Firmicutes compared with the healthy group. In addition, levels of species in the Proteobacteria phylum increased with progression from the healthy to obese to NASH groups, while the abundance of species in the Actinobacteria phylum (specifically those of the genus Bifidobacterium) decreased with worsening health status. The gut microbiome composition of obese patients and patients with NASH was similar, except for increased levels of Proteobacteria (specifically those of the Enterobacteriaceae family and the genus Escherichia; P < 0.05 for all three levels of classification) in the NASH group compared with the obese group. Increased abundance of ethanol-producing bacteria in the NASH microbiome prompted the investigators to measure serum alcohol levels in the three groups. While little to no difference was noted in ethanol levels between the healthy and obese groups, ethanol levels were significantly increased in the NASH vs the obese groups (P < 0.01).
Combined with the demonstration of increased abundance of Escherichia in patients with NASH, the authors theorised a pathophysiologic mechanism linking the altered microbiome in NASH and which may activate stellate cells and fibrogenesis. These factors are integral in the promotion of inflammation and the progression of fibrosis to cirrhosis in many diseases, such as viral hepatitis, biliary liver disease and NAFLD. 112, 114 In addition, a case-control/cross-sectional study has shown that trimethylamine-N-oxide, the liver product of a bacterial metabolite of choline, is associated with hepatic steatosis and inflammation. 87 Neither of these studies had any subgroup analysis of patients with and without insulin resistance or other confounding variables that may also affect gut microbiota. 19, 110, 111 However, there may be a future role for the gut microbiome to be used as a non-invasive marker to determine the presence of NASH and advanced fibrosis.
However, further studies, with larger cohorts, are needed before this marker can be recommended for diagnosis and prognosis of NASH.
Thus, while additional studies are warranted to validate the promise of gut microbial profiling, the gut microbiome in these patient populations may one day serve as an emerging tool for non-invasive diagnosis of disease severity and monitoring progression.
| G UT MI CROB I OTA AND B ILE ACIDS
BA composition is influenced by gut microbiota, and BAs are also thought to play a role in the development of NAFLD. 
| TRE ATMENTS FOR NAFLD THAT TARG E T G UT MI CROB I OTA
Historically, the mainstay of treatment for patients with NAFLD has been lifestyle modification (eg, diet, exercise and weight loss) and the correction of underlying risk factors (eg, tight control of T2DM). 108 Most pharmacologic treatments for NAFLD are designed to improve insulin sensitivity (eg, metformin, thiazolidinediones liraglutide and sitagliptin), reduce oxidative stress (vitamin E, ursodeoxycholic acid and pentoxifylline) or downregulate fibrosis mechanisms (angiotensin receptor blockers). 125 Unfortunately, these medications have not demonstrated consistent improvement in liver fibrosis. [125] [126] [127] Alternatively, data are accumulating on the potential role of therapies that alter gut microbiota in the treatment of patients with NAFLD and NASH.
| Prebiotics
Prebiotics are indigestible foods that promote the growth of beneficial GI bacteria through the fermentation of the prebiotic into SCFA. 128 Preclinical studies of prebiotics have shown improvement in biochemical and histologic markers of NAFLD. 129 One randomised trial (placebo crossover design) has been published to date. 130 In patients with biopsy-proven NASH (n = 7), prebiotic administration (ie, oligofructose 16 g/d) significantly reduced hepatic levels of aspartate aminotransferase (AST; P < 0.05 vs placebo) and nonsignificantly decreased TG concentrations compared with placebo after 8 weeks of treatment. However, a systematic review that included four clinical studies of patients with obesity-related NAFLD did not support the use of prebiotics, due to a lack of study quality. 131 
| Probiotics
Probiotics are living microorganisms that are ingested and improve the mucosal integrity of the GI tract through alteration of the gut microbiota (via competitive colonisation and by acidification of the GI lumen). 128 To date, six double-blind, randomised controlled trials, [132] [133] [134] [135] [136] [137] one open-label, randomised controlled trial 138 and one open-label, single-treatment trial 139 have examined the effect of probiotics in patients with NAFLD ( Table 1 inhibits FXR signalling within the intestinal wall, leading to decreased ceramide production. 115 Decreased ceramide production causes hepatic SREBP1C inhibition and decreased hepatic fatty acid accumulation. These findings were replicated in a rat study that showed alterations in the tissue BA profile, steroid biosynthesis and FXR signalling pathways after streptomycin and penicillin administration. 144 As in the previous study, elevated levels of tauro-beta-muricholic acid were observed, although this time in the liver.
Several human studies of antibiotics in NAFLD have assessed the effect of rifaximin, a nonsystemic antibiotic (Table 2) . [145] [146] [147] Rifaximin is currently indicated in the United States to prevent overt hepatic encephalopathy recurrence and to treat travellers' diarrhoea and irritable bowel syndrome (IBS) with diarrhoea. 148, 149 Although one may hypothesise that rifaximin exerts its effect by altering the composition of the gut microbiota, data have shown only modest changes in the components of the gut microbiome in patients with cirrhosis and hepatic encephalopathy after rifaximin treatment.
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Additionally, preclinical studies have indicated that the efficacy of rifaximin may be attributable to its beneficial effects on host cell physiology and bacterial gene expression.
151-153

| Faecal transplantation
Faecal transplantation has been used successfully in the treatment of patients with refractory and recurrent Clostridium difficile. 154, 155 Although no human studies have examined the role of faecal transplantation for NAFLD, this strategy may be a potential avenue for exploration. In mouse models of NAFLD, animals that underwent a faecal transplantation from wild-type mice donors showed decreased hepatic gluconeogenesis 156 and reduced intestinal permeability 157 (Table 3) . However, faecal transplantation is not without
TA B L E 1 Human studies of probiotics for NAFLD
Publication
Study population Study design/treatments Primary outcomes
Miccheli et al 2015
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Obese children with elevated ALT and ultrasonographic and histologic evidence of NAFLD DB, RCT; patients received placebo or the probiotic medical food VSL#3 a qd
(1 package for patients aged < 10 y and 2 packets for patients aged > 10 y) for 4 mo
• Among patients who completed the study (n = 22 for both groups), BMI, AST, total and active GLP-1 levels, and presence of fatty liver at 4 mo significantly improved in the probiotic group vs the placebo group (P < 0.05) • No significant differences in TGs, cholesterol, HDL, LDL or glycometabolism indices (glucose, insulin and HOMA-IR) were observed between groups at 4 mo • Key metabolites (valine, 3-aminoisobutyrate, alanine, tyrosine and pseudouridine) were significantly lower in the probiotic group vs placebo group at month 4 (P < 0.05), indicating an effect on BCAA and AAA metabolism, oxidative stress and microbiota metabolic pathways and neurologic conditions. 165 Two separate studies assessing the efficacy of FMT in the treatment of IBD found that patients who had received stool transplants from a particular donor had a higher success rate in inducing clinical and endoscopic remission compared with patients who did not receive stool from the "super donors." 160, 161 FMTs using stool obtained from lean donors transplanted into patients with metabolic syndrome led to a greater degree of improvement in peripheral insulin sensitivity compared with autologous FMT. 166, 167 Thus far, the only factor that seems to predict a successful FMT is the diversity of gut microbiota in the donor; conversely, recipients who are able to increase their faecal microbiome diversity to a higher degree in response to FMT were more likely to have successful outcomes in treatment of the underlying disease.
168,169
| CON CLUS IONS
The GI tract and the liver develop from the same embryologic origins in the foregut, and this close interrelationship is maintained.
Obesity, diet and insulin resistance are common risk factors for the development of NAFLD, 15, 83, 84 and these risk factors seem to have a strong connection with the gut microbiome. 12 While diet and obesity play a role in the modification of bacteria in the gut microbiota, the bacteria, in turn, affect the ability of host cells to produce and absorb nutrient-derived energy. 34 SCFAs and the ra- Obesity and insulin resistance are also associated with increased intestinal permeability [171] [172] [173] and, therefore, increased rates of bacterial translocation, which activates proinflammatory cascades. 84, 170, 174, 175 Kupffer cell activation by bacterial products such as LPS results in oxidative stress and the development of hepatocyte inflammation and fibrosis. LPS also promote the development of hepatic TG accumulation and hepatic steatosis. 12, 100, 112, 113 There is a strong association between bacterial translocation and the degree of hepatic decompensation in the setting of cirrhosis of any aetiology, 174 and among gut microbiota, BA metabolism, FXR and hepatic steatosis and inflammation. • No significant alterations from baseline in ALT, hepatic lipid content, hepatic insulin sensitivity or serum cytokine (TNF-α and IL-1β) after 6 wk • ALT (P = 0.017), HDL (P = 0.004) and HOMA-IR (P = 0.05) levels significantly increased from baseline to week 12 (ie, during the 6-wk post-treatment period) • No consistent differences were observed in faecal microbiota composition at the phylum level • Significant reduction in urinary hippurate levels with rifaximin treatment (P = 0.048) was reported, indicating possible alteration in gut microbiota metabolism In addition, activation of TLRs by bacterial products results in increased systemic and hepatic inflammation, a major stimulus in the development of NASH and the progression to fibrosis. 100, 112, 113 Thus, treatment options aimed at targeting the gut microbiome, or the downstream cellsignalling effects of the microbiome, continue to be therapeutic targets for the treatment of patients with NAFLD. 
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